
|Videos|June 7, 2013
Using Selumetinib in Advanced Uveal Melanoma
Author(s)Richard D. Carvajal, MD
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Advertisement
Richard D. Carvajal, MD, medical oncologist, Memorial Sloan-Kettering Cancer Center, describes the use of selumetinib in patients with advanced uveal melanoma.
Clinical Pearls
The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma. Even though trametinib (another MEK inhibitor) was recently approved, Carvajal says that clinical trials are still the most appropriate area for treatment with MEK inhibitors in uveal melanoma.
- The trial exploring selumetinib was the first ever to find an agent that demonstrated efficacy for patients with advanced uveal melanoma
- Clinical trials are still the most appropriate area for treatment with MEK inhibitors in this disease type
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Enfortumab Vedotin Plus Pembrolizumab Improves Survival in MIBC
2
Teclistamab/Daratumumab Earns FDA Priority Voucher for R/R Myeloma
3
Early Relapse Guides Use of CAR T vs Other Options in LBCL
4
FDA Grants Regular Approval to Rucaparib for BRCA-Mutated mCRPC
5








































